Lifecore Biomedical (LFCR) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Pyxis Oncology (PYXS) over the past year, losing 4.5% versus a loss of 21.2%. Over five years, LFCR leads with a -34.4% price change compared with -82.9% for PYXS. Lifecore Biomedical is the larger company by market cap ($244.1 million vs $240.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFCR | PYXS |
|---|---|---|
| Share price | $6.44 | $2.01 |
| Market cap | $244.11M | $240.11M |
| 1-day change | -0.16% | -0.50% |
| YTD return | -21.27% | +74.78% |
| 1-year return | -4.45% | -21.18% |
| 5-year return | -34.35% | -82.92% |
| EPS (TTM) | $-1.27 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.98 | $5.55 |
| 52-week low | $3.63 | $1.03 |
| Distance from 52-week high | -28.29% | -63.78% |
| Analyst consensus | hold | none |
| Avg. price target upside | -2.48% | +331.34% |
| Average volume | 264.01K | 1.26M |
| Shares outstanding | 37.91M | 119.46M |
| Employees | 382 | 56 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed PYXS by 16.7 percentage points over the past year.
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Healthcare · Drug Manufacturers - Specialty & Generic · 382 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Healthcare · Biotechnology · 56 employees
LFCR vs PYXS FAQ
Which is bigger, Lifecore Biomedical or Pyxis Oncology?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $244.11M compared with $240.11M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, LFCR or PYXS?
LFCR returned -4.45% over the past 12 months, compared with -21.18% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Lifecore Biomedical and Pyxis Oncology in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Lifecore Biomedical and Biotechnology for Pyxis Oncology.